<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2099">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133830</url>
  </required_header>
  <id_info>
    <org_study_id>213688</org_study_id>
    <nct_id>NCT05133830</nct_id>
  </id_info>
  <brief_title>Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants</brief_title>
  <official_title>A Two-part, Phase 1, Open-label, Randomized, Parallel-arm, Fixed Sequence, Drug-drug Interaction Study to Investigate the Effect of Linerixibat on Plasma Concentrations of Obeticholic Acid and Conjugates in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the effect of linerixibat on plasma concentrations of&#xD;
      obeticholic acid (OCA) and its conjugates in healthy adult participants to inform the&#xD;
      potential for drug interaction with coadministration of linerixibat and OCA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 23, 2021</start_date>
  <completion_date type="Anticipated">October 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two arms will be evaluated in parallel in Part A. After Part A, if Part B is conducted, one of the two remaining arms will be evaluated.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average trough concentration (Ctrough) in plasma for total-OCA at steady state</measure>
    <time_frame>Days 35 to 38</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve from time 0 to t (AUC0-t) for OCA, tauro-OCA, glyco-OCA and total-OCA at steady state</measure>
    <time_frame>At Day 18 and Day 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time 0 to 24 hour (AUC0-24) for OCA, tauro-OCA, glyco-OCA and total-OCA at steady state</measure>
    <time_frame>Up to 24 hours on Day 18 and Day 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for OCA, tauro-OCA, glyco-OCA and total-OCA at steady state</measure>
    <time_frame>At Day 18 and Day 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average trough concentration (Ctrough) in plasma for OCA, tauro-OCA, glyco-OCA and total-OCA at steady state</measure>
    <time_frame>Days 17 to 19 and Days 35 to 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax) for OCA, tauro-OCA, glyco-OCA and total-OCA</measure>
    <time_frame>At Day 18 and Day 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of total OCA over Days 17 to 19 and Days 35 to 38</measure>
    <time_frame>Days 17 to 19 and Days 35 to 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to Day 52</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive OCA at dose level 1, 4 hours after the linerixibat administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive OCA at dose level 2 along with linerixibat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive OCA at dose level 1 along with linerixibat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive OCA at dose level 2, 4 hours after the linerixibat administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obeticholic acid</intervention_name>
    <description>OCA will be administered</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_label>Treatment Arm 3</arm_group_label>
    <arm_group_label>Treatment Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linerixibat</intervention_name>
    <description>Linerixibat will be administered</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_label>Treatment Arm 3</arm_group_label>
    <arm_group_label>Treatment Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overtly healthy male or female participants 18 to 50 years of age inclusive, at the&#xD;
             time of signing the informed consent&#xD;
&#xD;
          -  Body weight greater than (&gt;) 50 kilogram (kg) and body mass index (BMI) within the&#xD;
             range 18.5 - 32 kilogram per meter square (kg/m^2) (inclusive)&#xD;
&#xD;
          -  Capable of giving signed informed consent as the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any active dermatologic disorder leading to or with the potential to cause itching or&#xD;
             a recent history of unexplained clinically significant itching locally or generally&#xD;
             within the prior 3 months&#xD;
&#xD;
          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones) and/or confirmed&#xD;
             hepatocellular carcinoma or biliary cancer&#xD;
&#xD;
          -  History of gall bladder removal&#xD;
&#xD;
          -  Current symptomatic gallstones or inflammatory gall bladder disease&#xD;
&#xD;
          -  Significant history of or current disorders that can significantly alter the&#xD;
             absorption, metabolism, or elimination of drugs&#xD;
&#xD;
          -  Current clinically significant diarrhea&#xD;
&#xD;
          -  History of gastrointestinal surgery with ileal resection or ileal bypass at any time&#xD;
&#xD;
          -  Any malignancy within the past 5 years except for basal cell or squamous epithelial&#xD;
             carcinomas of the skin that have been resected with no evidence of metastatic disease&#xD;
             for 3 years&#xD;
&#xD;
          -  Administration of any other ileal bile acid transport (IBAT) inhibitor (including&#xD;
             linerixibat) or Ocaliva in the 3 months prior to screening&#xD;
&#xD;
          -  Past or intended use of over-the-counter or prescription medication, including&#xD;
             vitamins and dietary or herbal supplements) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inhibitor) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication, unless approved by the Investigator in conjunction with GSK&#xD;
&#xD;
          -  Current enrolment in a clinical trial or recent participation in a clinical trial and&#xD;
             has received an investigational product within 30 days before the first dose in the&#xD;
             current study&#xD;
&#xD;
          -  Exposure to more than 4 new chemical entities within 12 months before the first dose&#xD;
             in the current study&#xD;
&#xD;
          -  Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;1.5x&#xD;
             upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &gt;1.5xULN (isolated bilirubin &gt;1.5x ULN is acceptable if bilirubin is&#xD;
             fractionated and direct bilirubin lesser than (&lt;)35%&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test or&#xD;
             positive hepatitis C riboneucleic acid (RNA) test result at screening or within 3&#xD;
             months prior to first dose of study intervention&#xD;
&#xD;
          -  Positive pregnancy test at screening or at Day -1&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) antibody test&#xD;
&#xD;
          -  QT interval corrected (QTc) &gt;450 millisecond (msec)&#xD;
&#xD;
          -  Regular use of known drugs of abuse or history of drug abuse or dependence within 6&#xD;
             months of the study&#xD;
&#xD;
          -  Participants with moderate (or greater) alcohol consumption&#xD;
&#xD;
          -  History of or regular use of tobacco- or nicotine-containing products in the 3 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Female participants unable or unwilling to comply with specific contraception&#xD;
             restrictions as detailed in the protocol&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 milliliter (mL) within a 56-day period&#xD;
&#xD;
          -  Sensitivity to any of the study interventions, or components thereof, or drug or other&#xD;
             allergy that, in the opinion of the investigator or GSK Medical Monitor,&#xD;
             contraindicates participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Linerixibat</keyword>
  <keyword>Obeticholic acid</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

